SLC2A1 and Miyoshi myopathy: Gain-of-function studies in MM and paediatric AML have shown that expression of miR-489 and miR-34b inhibits aerobic glycolysis by reducing glucose uptake, lactate, and ATP production by directly targeting GLUT1.